National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial
Author:
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10549-023-07114-8.pdf
Reference65 articles.
1. Masuda N, Lee S-J, Ohtani S et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147–2159. https://doi.org/10.1056/nejmoa1612645
2. Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810–821. https://doi.org/10.1056/nejmoa1910549
3. Mittendorf EA, Zhang H, Barrios CH et al (2020) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396(10257):1090–1100. https://doi.org/10.1016/S0140-6736(20)31953-X
4. Loibl S, Schneeweiss A, Huober J et al (2022) Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 33(11):1149–1158. https://doi.org/10.1016/j.annonc.2022.07.1940
5. Malorni L, Shetty PB, De Angelis C et al (2012) Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat 136(3):795–804. https://doi.org/10.1007/s10549-012-2315-y
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Neoadjuvant chemotherapy for breast cancer in Italy: A Senonetwork analysis of 37,215 patients treated from 2017 to 2022;The Breast;2024-08
2. The Prevalence of Sentinel Lymph Node Positivity and Implications for the Utility of Frozen Section Diagnosis Following Neoadjuvant Systemic Therapy in Patients with Clinically Node-Negative HER2-Positive or Triple-Negative Breast Cancer;Annals of Surgical Oncology;2024-07-24
3. Shifting neoadjuvant chemotherapy treatment paradigms for breast cancer and its impact on axillary nodal management for clinically node-negative patients;Gland Surgery;2024-07
4. ASO Author Reflections: Neoadjuvant Systemic Therapy and Nodal Management in cT1-2 N0 Triple-Negative Breast Cancer;Annals of Surgical Oncology;2024-02-10
5. Does Neoadjuvant Chemotherapy in Clinical T1–T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery?;Annals of Surgical Oncology;2024-01-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3